From ImmusanT, Developing Celiac Disease Treatments, Closes $20M Series A:

ImmusanTLogo

ImmusanTLogo—

ImmusanT is developing therapies for celiac disease

Underwriters and Partners

Xconomy Insight

From Our Editors · Special Report
Xcelerating Life Sciences San Francisco: Special Report
The AI, Big Data, and R&D Boom

Sponsored · Whitepaper
What to Include in Your Life Sciences Company Fundraising Pitch Deck
What the most successful life sciences fundraising pitch decks all have in common
Brex

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

Xconomy on Demand

We offer a number of ways to subscribe for free!